Metraipolis › archive › dc_7f7683bc318c

Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists — Europe PMC PMID:42195313

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42195313
DOI
10.3390/life16050756
License (as archived)
solo-consultazione
Archived
2026-11-02T22:02:38.709Z
SHA-256 of the archived text
0f515c3f9da9cfaac9d0e4908ff233684c6f49a7322070392fe20598062d4704
Stable URL of this page
https://metraipolis.com/documento/dc_7f7683bc318c

How to cite

Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists — Europe PMC PMID:42195313 — Europe PMC (en), https://europepmc.org/article/MED/42195313 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7f7683bc318c (Metraipolis archive dc_7f7683bc318c, sha256 0f515c3f9da9cfaac9d0e4908ff233684c6f49a7322070392fe20598062d4704)
BibTeX
@misc{dc7f7683bc318c,
  title = {Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists — Europe PMC PMID:42195313},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42195313},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7f7683bc318c; sha256 0f515c3f9da9cfaac9d0e4908ff233684c6f49a7322070392fe20598062d4704},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42195313. Agents can read the archived copy with the MCP tool read_document.